source
- MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trialMoonLake Immunotherapeutics announced positive phase 3 data of patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.Fierce Biotech · 10h ago↗ source
- BlossomHill and Latigo Biotherapeutics raise over 30% beyond IPO targetsTwo emerging biotech companies surpassed their initial public offering expectations on Friday, with both BlossomHill Therapeutics and Latigo Biotherapeutics raising at least 30% more capital than p…